Tubulins as therapeutic targets in cancer: from bench to bedside

scientific article

Tubulins as therapeutic targets in cancer: from bench to bedside is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2174/138161212800626193
P698PubMed publication ID22390762
P5875ResearchGate publication ID221888425

P50authorPavel DráberQ102053371
Christos D KatsetosQ117803393
P433issue19
P407language of work or nameEnglishQ1860
P304page(s)2778-92
P577publication date2012-01-01
P1433published inCurrent Pharmaceutical DesignQ5195068
P1476titleTubulins as therapeutic targets in cancer: from bench to bedside
P478volume18

Reverse relations

cites work (P2860)
Q64892794A Survey on Tubulin and Arginine Methyltransferase Families Sheds Light on P. lividus Embryo as Model System for Antiproliferative Drug Development.
Q61453755Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action
Q58547427Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives
Q36562191Bis-cyclopropane analog of disorazole C1 is a microtubule-destabilizing agent active in ABCB1-overexpressing human colon cancer cells
Q38404084Class III β-tubulin in normal and cancer tissues
Q34155176Computational identification of surrogate genes for prostate cancer phases using machine learning and molecular network analysis
Q38015371Cytoskeleton in mast cell signaling
Q37447324Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.
Q27005747Epothilones: From discovery to clinical trials
Q38954268Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells
Q89932847Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action
Q34313834Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells.
Q38816570MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation
Q38984991Microtubule Destabilization Paves the Way to Parkinson's Disease.
Q38726651Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
Q38863581Overexpression and Nucleolar Localization of γ-Tubulin Small Complex Proteins GCP2 and GCP3 in Glioblastoma
Q49849048Radiosynthesis and in vivo evaluation of [11C]MPC-6827, the first brain penetrant microtubule PET ligand.
Q64974153Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.
Q38852408Repurposing of phentolamine as a potential anticancer agent against human castration-resistant prostate cancer: A central role on microtubule stabilization and mitochondrial apoptosis pathway
Q64097833Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
Q90163186Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine
Q59794796Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents
Q38092648The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
Q89966987Upregulated Expression of TUBA1C Predicts Poor Prognosis and Promotes Oncogenesis in Pancreatic Ductal Adenocarcinoma via Regulating the Cell Cycle
Q38933291Use of Integrated Computational Approaches in the Search for New Therapeutic Agents
Q28284878βIII-Tubulin: biomarker of taxane resistance or drug target?

Search more.